A rapid screening with direct sequencing from blood samples for the diagnosis of Leigh syndrome

Hiroko Shimboa, Mariko Takagia, Mitsuko Okuda a, Yu Tsuyusaki a, Kyoko Takano a, Mizue Iai a, Sumimasa Yamashitaa, Kei Murayamac, Akira Ohtaked, Yu-ichi Gotoe, Noriko Aidab, Hitoshi Osakaa,f,⁎

a Division of Neurology, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa, Minami-ku, Yokohama, Kanagawa 232-8555, Japan
b Division of Radiology, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa, Minami-ku, Yokohama, Kanagawa 232-8555, Japan
c Department of Metabolism, Chiba Children's Hospital, 579-1, Heta-cho, Midori-ku, Chiba-shi, Chiba 266-0007, Japan
d Department of Pediatrics, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Hruma-gun, Saitama 350-0495, Japan
e Department of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi-machi, Kodaira-shi, Tokyo 187-8551, Japan
f Department of Pediatrics, Jichi Medical School, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan

A R T I C L E   I N F O

Article history:
Received 12 February 2014
Accepted 12 February 2014
Available online 1 April 2014

Keywords:
Leigh syndrome
Complex I deficiency
Heteroplasmy
mtDNA mutation

A B S T R A C T

Large numbers of genes are responsible for Leigh syndrome (LS), making genetic confirmation of LS difficult. We screened our patients with LS using a limited set of 21 primers encompassing the frequently reported gene for the respiratory chain complexes I (ND1–ND6, and ND4L), IV(SURF1), and V(ATP6) and the pyruvate dehydrogenase E1α-subunit. Of 18 LS patients, we identified mutations in 11 patients, including 7 in mtDNA (two with ATP6), 4 in nuclear (three with SURF1). Overall, we identified mutations in 61% of LS patients (11/18 individuals) in this cohort. Sanger sequencing with our limited set of primers allowed us a rapid genetic confirmation of more than half of the LS patients and it appears to be efficient as a primary genetic screening in this cohort.

© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

Leigh syndrome (LS) (OMIM 256000) is an early onset, devastating neurodegenerative disease of the central nervous system (CNS) characterized by symmetrical necrotic lesions in the brainstem, basal

⁎ Corresponding author at: Dept. of Pediatrics, Jichi Medical School, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan.
Fax: +81 285 44 6123
E-mail address: hosaka@jichi.ac.jp (H. Osaka).

http://dx.doi.org/10.1016/j.ymgmr.2014.02.006
2214-4269/© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
ganglia and thalamus [1,2]. The symptoms of LS include psychomotor retardation, respiratory difficulties, nystagmus, hypotonia, seizures, myoclonus, ataxia, dystonia, ptosis, ophthalmoplegia and high lactate levels in the blood and cerebrospinal fluid. Mutations in both mitochondrial DNA (mDNA) and nuclear DNA cause LS [3].

LS arises from a deficiency in the enzymes relating to energy production in the mitochondria, such as the respiratory chain complexes I–V, and the pyruvate dehydrogenase complex. Among the enzymes, isolated complex I deficiency is the most frequent oxidative phosphorylation (OXPHOS) defect in children with LS [4,5], followed by a deficiency of complex IV (cytochrome C oxidase) and complex V (ATP synthase). Complex I is composed of seven mDNA encoded NADH dehydrogenase (ND) subunits (ND1–6, ND4L) and at least 38 nuclear DNA subunits [4]. An isolated generalized defect of complex IV is the second most common biochemical abnormalities found in patients with Leigh syndrome [6,7]. SURF1 mutations, which encode the putative assembly protein of complex IV, have been repeatedly reported [6].

Since a large number of genes are reportedly related to LS, molecular diagnosis appears challenging. However, emerging drugs for LS demand prompt diagnostic confirmation of LS. Although exome sequencing is a powerful method of suspected mitochondrial disorders, it is time and cost consuming, and impractical to be applied to all patients with LS. Based on the reported mutation information, we designed a small set of 21 primers that cover the gene in which LS mutations have been frequently reported [3].

In this study, we have examined the efficacy of our Sanger sequencing method as a genetic screening for LS in 18 unrelated LS cases from one children’s hospital. We identified 7 patients with point mutations in mDNA including 2 cases in the ATP6 gene and five in the ND genes. We also elucidated 4 mutations in the nuclear encoded gene, including 3 patients with a mutation in SURF1 and 1 patient with a mutation in PDHA1 (pyruvate dehydrogenase E1α-subunit). Our data suggest that Sanger screening using limited sets of primers is useful as first line screening for LS.

2. Methods

We identified 18 patients from 16 families that met the criteria of LS at our institution (2005–2012). Diagnoses of LS were defined as presenting progressive neurologic disease with signs and symptoms of brain stem and/or basal ganglia abnormalities revealed on MR images. The clinical courses are summarized in Table 1 and Supplementary text. We have designed primers encoding mitochondrial derived subunits for complex I (ND1–6, ND4L) [3]. Primers were also designed on frequently reported gene SURF 1 from complex IV [7] and ATP synthase from complex V [8]. If the blood lactate/pyruvate ratio is less than 10, we first sequenced the PDHA1 gene (Suppl. Fig. 1) [8]. Methods of genetic analysis, enzyme assays and determination of heteroplasmic rate and associated references are available in the online version of the paper (Suppl. Table 1, Suppl. Table 2, Suppl. text).

3. Results (Table 1, Suppl. Fig. 2)

Of 18 LS patients, we identified gene mutations in 11 patients from 11 families (Table 1, Suppl. Fig. 2). mDNA mutations were identified in 7 patients. An ND1 mutation of complex I (m3697G>A, p.Gly131Ser) was identified in 2 individuals with homoplasmy. Mutations in ND3 (m10158T>C, p.Ser34Pro; mutant rate 90% in white blood cell), ND5 (m13513G>N, p.Asp393Asn; mutant rate 50% in white blood cell) and ND6 (m14459G>N, p.Ala71Val, homoplasmic state) were identified in a single patient, respectively. One severe patient died at 1 year, and carried a mutation in ATP6 (m8993T>G, p.Leu156Arg) of OXPHOS as a homoplasmic state. Instead of T>G, T>N mutation of the same nucleotide, m8993T>N, p.Leu156Pro, was observed with homoplasmy in a milder case.

Four patients were identified with mutations in nuclear DNA. SURF1 mutations were identified in 3 cases, including 2 cases that were compound heterozygous (c.49+1G>T/c.752_753delAG) and (c.574C>T, p.Arg192Trp and c.743C>A, p.Ala248Asp) and 1 case that was homozygous (c.743C>A, p.Ala248Asp). One male patient was identified with a hemizygous mutation (c.121T>C, p.Cys41Arg) in PDHA1. Overall, we identified mutations in 61% of LS patients (11/18 individuals) in this cohort.
4. Discussion

Molecular elucidation of LS at the DNA level is challenging. LS has been associated with a variety of genes in either mitochondrial or nuclear encoded DNA [3]. Surprisingly, we could reveal mutations in 61% of LS patients (11/18 individuals).

We disclosed 7 patients with mDNA mutations. From mitochondrial ND1, we identiﬁed an m3697G→A mutation in 2 unrelated patients, which has been reported previously in association with mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes (MELAS) [9] and Leber’s hereditary optic neuropathy (LHON) [10]. To our knowledge, this is the ﬁrst report of the m3697G→A/ND1 gene mutation causing Leigh syndrome. The heteroplasmy rate is reportedly 80% in patients with MELAS (skeletal muscle) and was 56% with LOHN [9,10]. A high mutation load (100%), found in the blood of Patients 1 and 2 may be associated to severe phenotype in our patients [11]. Low level of m3697G→A mutation (~40%) was found in the blood from an asymptomatic mother of Patient 1 (Suppl. Figs. 3 and 4).

For ND3, we found a mutation of m10158T→C with 90% of heteroplasmic rate in one patient showing an early onset and very rapid progress. Severe clinical course and high mutant loads are consistent with reported cases with rapid progression and lethal consequences at early childhood [12]. A mutation of m10158T→C was not detected in the mother of Patient 3 in several tissues examined.

We found one patient with ND5 mutation, m13513G→A which has been described as causing MELAS, LS or overlapping features of the two syndromes [13–15]. We also found one LS patient with m14459G→A/ND6 mutation that was reported in patients with LHON, dystonia [16] and LS [17]. So far, the phenotype of these two patients is LS without MELAS, LHON.

We found two patients with ATPase6 mDNA mutations, m8993T→G and T→C, that are frequently reported in the literature [8]. A patient with a T→G mutation usually exhibits earlier onset and more rapid progression compared to T→C mutation at m8993 that was compatible with our patients (Table 1).

We found 4 patients carrying nuclear encoded gene mutations. SURF1 deﬁciency is the most frequent cause of LS with complex IV (cytochrome C oxidase) deﬁciency [7]. We identiﬁed 3 patients with the SURF1 mutations [18]. Pyruvate dehydrogenase deﬁciency (PDH) is a common cause of primary congenital lactic acidosis. The biochemical features of PDH deﬁciency is elevated blood lactate and pyruvate levels with a normal lactate/pyruvate ratio [19]. According to the genetic screening ﬂowchart for Leigh syndrome (Suppl. Fig. 1), we conﬁrmed 1 patient with a hemizygous mutation in the PDHA1 gene with 7 sets of primers.

Recently, new drugs such as EPI-743 have been shown to improve neurological and neuromuscular symptoms in LS [20,21]. Rapid genetic conﬁrmation of mitochondrial disease may help initiate such treatment early. Next gene sequencing is revealing a wide range of dual mutations both mitochondrial and nuclear gene from patients with mitochondrial disorders [22–24]. However, it is costly and time consuming. Aiming to elucidate genetic basis of LS patients, we screened with our limited set of primers. Surprisingly, it allowed us conﬁrmation for more than half of the patients. Therefore, this method appears to be efﬁcient as a primary genetic screening. Our data also implicates that LS consisted of few “common” causative genes and a large number of “rare” genes. We are now undertaking whole mDNA and exome sequencing for negative cases of this method [22–24]. These data, together with increasing data of mutations, would help us improve our screening method.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ymgmr.2014.02.006.

Conflict of interest statement

We have no conﬂict of interest to disclose.

Acknowledgments

This work was supported in part by a grant of the Innovative Cell Biology by Innovative Technology (Cell Innovation Program) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, by Grants-in-Aid of the Research on Intractable Diseases (Mitochondrial Disorder) from the Ministry of Health, Labour and Welfare of Japan (H23-N-I-016), and by Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics (24-12).
Table 1
Genetically determined Leigh syndrome in our institution (2005–2012).

| Patient | 1          | 2          | 3          | 4          | 5          | 6          | 7          | 8          | 9          | 10         | 11         |
|---------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Age, gender | 7 y, M    | 10 y, F    | 9 m, F    | 7 y, M    | 11 y, M    | 2 y, M    | 4 y, F    | 9 y, M    | 25 y t, M  | 17 y, M    |            |
| Type of gene | Mito ND1 | Mito ND1 | Mito ND3 | Mito ND5 | Mito ATPase6 | Mito ATPase6 | Nuclear SURFI | Nuclear SURFI | Nuclear SURFI | Nuclear PDHA1 |
| Gene Complex | I | I | I | I | V | V | IV | IV | IV | IV | IV |
| Mutations | m3697G>A (p.G131S) Homo (b) | m3697G>A (p.G131S) Homo (b) | m10158T>C (p.S34P) Hetero (90%) (b) | m13513G>A (p.D393N) Hetero (50%) (b) | m14459G>A (p.A71V) Homo (b) | m8993T>C (p.L156P) Homo (b) | m8993T>C (p.L156P) Homo (b) | m752–753delAG Homo (b) |
| Consanguinity Inheritance | N Maternal* hetero:40% | N N.A. | N De novo | N N.A. | N N.A. | N N.A. | N N.A. | Y Maternal/paternal | N N.A. | N N.A. |
| Consanguinity Inheritance | N Maternal* hetero:40% | 3 y 9 m Hypertonia | 0 y 5 m Ataxic gait | 1 y 6 m Dev. delay | 2 y 0 m Fever → lethargy | 6 m Dev. delay/ seizure | 1 y 0 m Fever → lethargy | 2 y Dev. delay | 1 y 0 m Dev. delay |
| Status | Walk Normal class | Wheelchair | Tracheo Mech. venti | Walk | Wheelchair | Normal class | Tracheo | Tracheo Mech. venti | (Respiratory failure) | Walk | Special class |
| Status | I, IV (m) | I, III, IV (m) | I (f) | Normal (m/f) | I, III (m) | I, IV (m) | N.A. | N.A. | IV (f) | IV (m) | N.A. |
| RC enzymes ↓ | No RRF | No RRF | N.A. | Normal (m/f) | No RRF | RRF | N.A. | N.A. | N.A. | RRF | N.A. |
| Morphological findings in muscle | No RRF | No RRF | N.A. | Normal (m/f) | No RRF | RRF | N.A. | N.A. | N.A. | RRF | N.A. |
| MRI                  | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|---------------------|---|---|---|---|---|---|---|---|---|---|---|
| Basal ganglia       | N | Y | Y | N | N | N | Y | Y | Y | Y | N |
| hyperintensities    |   |   |   |   |   |   |   |   |   |   |   |
| Brainstem           | N | N | N | Y | N | N | N | N | N | Y | Y |
| hyperintensities    |   |   |   |   |   |   |   |   |   |   |   |
| Cerebellar atrophy  | N | N | N | Y | N | N | N | N | N | Y | Y |
| Symptoms            |   |   |   |   |   |   |   |   |   |   |   |
| Dysmorphisms        | N | N | N | N | N | N | N | N | Y | Y | N |
| Developmental delay | N | N | Y | Y | N | N | N | Y | Y | Y | Y |
| Regression          | Y | Y | Y | N | N | N | Y | Y | Y | Y | Y |
| Feeding problems    | N | N | N | N | N | N | N | N | N | N | Y |
| Ptosis              | N | N | N | N | N | N | N | N | Y | N | N |
| Ophthalmople        | N | N | Y | N | N | N | N | N | Y | N | Y |
| Pyramidal symptoms  | Y | Y | Y | Y | Y | Y | N | N | Y | Y | N |
| Extrapyramidal      | Y | Y | Y | Y | Y | Y | N | Y | N | Y | Y |
| symptoms            |   |   |   |   |   |   |   |   |   |   |   |
| Dystonia            | Y | Y | Y | N | N | N | N | Y | Y | Y | N |
| Hypotonia           | N | N | Y | Y | N | N | Y | Y | Y | N | Y |
| Ataxia              | Y | Y | Y | Y | N | N | N | Y | Y | Y | Y |
| Neuropathy          | N | N | N | N | N | N | N | Y | Y | Y | Y |
| Others              | WPW syndrome |   |   |   |   |   |   |   |   |   |   |

y: year, m: month, M: male, F: female, mito: mitochondria, Complex: complex in oxidative phosphorylation, b: blood, s: saliva, h: hair, n: nail, RC: respiratory chain, m: muscle, f: fibroblast, RRF: ragged red fibers, N.A.: not analyzed/not determined, N: no, negative, Y: yes, positive, regre: regression, Dev. delay: Developmental delay, Mech.venti: Mechanically ventilated, Ophthalmople: Ophthalmoplegia, *: asymptomatic.
References

[1] D. Leigh, Subacute necrotizing encephalomyelopathy in an infant, J. Neurol. Neurosurg. Psychiatry 14 (1951) 216–221.

[2] S. Rahman, R.B. Blok, H.H. Dahl, D.M. Dans, D.M. Kirby, C.W. Chow, J. Christodoulou, D.R. Thorburn, Leigh syndrome: clinical features and biochemical and DNA abnormalities, Ann. Neurol. 39 (1996) 343–351.

[3] J. Finsterer, Leigh and Leigh-like syndrome in children and adults, Pediatr. Neurol. 39 (2008) 223–235.

[4] E. Fassone, S. Rahman, Complex I deficiency: clinical features, biochemistry and molecular genetics, J. Med. Genet. 49 (2012) 578–590.

[5] S. Koene, R.J. Rodenburg, M.S. van der Knaap, M.A. Willemsen, W. Sperli, V. Laugel, E. Ostergaard, M. Tarnopolsky, M.A. Martin, V. Nesbit, J. Fletcher, S. Edvardson, V. Procaccio, A. Slama, L.P. van den Heuvel, J.A. Smeitink, Natural disease course and genotype–phenotype correlations in complex I deficiency caused by nuclear gene defects: what we learned from 130 cases, J. Inherit. Metab. Dis. 35 (2012) 737–747.

[6] Z. Zhu, J. Yao, T. John, K. Fu, I. De Bie, C. Macmillan, A.P. Cuthbert, R.F. Newbold, J. Wang, M. Chevrette, G.K. Brown, R.M. Brown, E.A. Shoubridge, SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome, Nat. Genet. 20 (1998) 337–343.

[7] Y. Wedatilake, R. Brown, R. McFarland, J. Yaplito-Lee, A.A. Morris, M. Champion, P.E. Jardine, A. Clarke, D.R. Thorburn, R.W. Taylor, J.M. Land, K. Forrest, A. Dobbie, L. Simmons, E.T. Asseme, D. Ketteridge, D. Hanrahan, A. Chakrapani, G.K. Brown, S. Rahman, SURF1 deficiency: a multi-centre natural history study, Orphanet J. Rare Dis. 8 (2013) 96.

[8] M. Makino, S. Horai, Y. Goto, I. Nonaka, Mitochondrial DNA mutations in Leigh syndrome and their phylogenetic implications, J. Hum. Genet. 45 (2000) 69–75.

[9] D.M. Kirby, R. McFarland, A. Ohtake, C. Dunning, M.T. Ryan, C. Wilson, D. Ketteridge, D.M. Turnbull, D.R. Thorburn, R.W. Taylor, Mutations of the mitochondrial ND1 gene as a cause of MELAS, J. Med. Genet. 41 (2004) 784–789.

[10] L. Spruijt, H.J. Smeets, A. Hendrickx, M.W. Bettink-Remeijer, A. Maat-Kievit, K.C. Schoonderwoerd, W. Sluiter, I.F. de Coo, R.Q. Hintzen, A MELAS-associated ND1 mutation causing leber hereditary optic neuropathy and spastic dystonia, Arch. Neurol. 64 (2007) 890–893.

[11] A.L. Mitchell, J.L. Elson, N. Howell, R.W. Taylor, D.M. Turnbull, Sequence variation in mitochondrial complex I genes: mutation or polymorphism?, J. Med. Genet. 33 (1996) 175–179.

[12] R. McFarland, D.M. Kirby, K.J. Fowler, A. Ohtake, M.T. Ryan, D.J. Amor, J.M. Fletcher, J.W. Dixon, F.A. Collins, D.M. Turnbull, R.W. Taylor, D.R. Thorburn, De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy with multisystem failure, Ann. Neurol. 55 (2004) 58–64.

[13] A. Sudo, S. Honzawa, I. Nonaka, Y. Goto, Leigh syndrome caused by mitochondrial DNA G13513A mutation: frequency and clinical features in Japan, J. Hum. Genet. 49 (2004) 92–96.

[14] M. Crimi, S. Galbiati, I. Moroni, A. Bordoni, M.P. Perini, E. Lamoneta, M. Sciacco, M. Zeviani, I. Biunno, M. Moggio, G. Scarlato, G.P. Comi, A missense mutation in the mitochondrial ND5 gene associated with a Leigh–MELAS overlap syndrome, Neurology 60 (2003) 1857–1861.

[15] A. Brautbar, J. Wang, J.E. Abdenur, R.C. Chang, J.A. Thomas, T.A. Grebe, C. Lim, S.W. Weng, B.H. Graham, L.J. Wong, The mitochondrial 13513G–A mutation is associated with Leigh disease phenotypes independent of complex I deficiency in muscle, Mol. Genet. Metab. 94 (2008) 485–490.

[16] A. Gropman, T.J. Lan, C.L. Perng, D. Krasnewich, E. Chernoff, C. Tifft, L.J. Wong, Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation, Ann. Med. Genet. A 124A (2004) 377–382.

[17] D.M. Kirby, S.G. Kahler, M.L. Freckmann, D. Reddihough, D.R. Thorburn, Leigh disease caused by the mitochondrial DNA G14459A mutation in unrelated families, Ann. Neurol. 48 (2000) 102–104.

[18] J. Tanigawa, K. Kaneko, M. Honda, H. Harashima, K. Murayama, T. Wada, K. Takano, M. Iai, S. Yamashita, H. Shimbo, N. Aida, A. Ohtake, H. Osaka, Two Japanese patients with Leigh syndrome caused by novel SURF1 mutations, Brain Dev. 34 (2012) 861–865.

[19] L. De Meirleir, Defects of pyruvate metabolism and the Krebs cycle, J. Child Neurol. 17 (Suppl. 3) (2002) 3526–33 (discussion 3533–24).

[20] A.A. Sadun, C.F. Chicani, F.N. Ross-Cisneros, P. Barboni, M. Thoolen, W.D. Shrader, K. Kubis, V. Carelli, G. Miller, Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy, Arch. Neurol. 69 (2012) 331–338.

[21] D. Martinelli, M. Catteruccia, F. Piemonte, A. Pastore, G. Tozzi, F. Pontrelli, C. Dionisi-Vici, G. Pontrelli, T. Corsetti, S. Livadiotti, V. Kheifets, A. Hinman, W.D. Shrader, M. Tholen, M.B. Klein, E. Bertini, G. Miller, EPI-743 reverses the progression of the pediatric mitochondrial disease—genetically defined Leig syndrome, Mol. Genet. Metab. 107 (2012) 383–388.

[22] D.S. Lieber, S.E. Calvo, K. Shanahan, N.G. Slate, S. Liu, S.G. Hershman, N.B. Gold, B.A. Chapman, D.R. Thorburn, G.T. Berry, J.D. Schmahmann, D.L. Markow, D.M. Mueller, T.M. Sims, K.V. Mootha, Targeted exome sequencing of suspected mitochondrial disorders, Neurology 80 (2013) 1762–1770.

[23] J.T. Dare, V. Vasta, J. Penn, N.T. Tran, S.H. Hahn, Targeted exome sequencing for mitochondrial disorders reveals high genetic heterogeneity, BMC Med. Genet. 14 (2013) 118–126.

[24] D.L. Dinwiddie, L.D. Smith, N.A. Miller, A.M. Ahtheron, E.G. Farrow, M.E. Strenk, S.E. Soden, C.J. Saunders, S.F. Kingsmore, Diagnosis of mitochondrial disorders by concomitant next-generation sequencing of the exome and mitochondrial genome, Genomics 102 (2013) 148–156.